SYHA 1805
Alternative Names: SYHA-1805Latest Information Update: 27 Apr 2022
At a glance
- Originator CSPC Pharmaceutical Group
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 30 Mar 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis in China (PO)
- 27 Jul 2021 CSPC ZhongQi Pharmaceutical Technology plans a phase I trial in Healthy volunteers in China (PO, Tablet) (NCT04977570)
- 27 Nov 2020 CSPC Pharmaceutical Group plans a phase I trial for Healthy volunteers in China (PO) (NCT04645901)